Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (209)	11/24/1999 6:03:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 557

I bought more TGEN today at 1 7/8. If the publicity coming out of the ASH meeting Dec. 4-6 is good for Avigen, the investment community will start looking around for who else, besides Avigen, has a good foothold in AAV. Remember when Entremed's stock we through the roof, every small biotech company with an anti-angiogenesis drug in development saw its stock rise too. The share price of Avigen has already run up so much in anticipation of the news, it is hard to tell how much pop there will be left. Even with a bunch of new buyers, the momentum players who have been bidding up the stock may match the new demand with an ample supply. Stocks like ARIA and TGEN, which have not moved nearly so much, might see bigger pops that Avigen will. Caveat: the ASH news could be underwhelming. From the abstract posted by Avigen, it looks like the dosage of the patients being reported on may have been too small to produce a therapeutic effect. Much may depend upon how well Avigen pitches the news. Marc

To: biowa who wrote (209)	11/30/1999 2:14:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

<Barrie Carter> You may already subscribe...but I stumbled onto this and thought it might interest you and the rest of the folks on this thread. current-drugs.com Clinical Applications of Gene Therapy Edited by Barrie Carter (Targeted Genetics Corp, USA) Don Kohn (Los Angeles Children's Hospital, USA) _______________________ (Banter) I envy scientists like these fellas, and yourself. We have a science officer down at the Weather Service-- always "away on business." That leaves the rest of us behind to man the shop, where at times, we do rather feeble science--living off the work of the numerical modelers and computer nerds. It's a nice niche, being a weather forecaster, but I witness poor thinking and bad science far too often. (I contribute the lousy grammar at work). I hope I can somehow sniff out the little biotech companies that are lead by good science, from those that are all hype, smoke and mirrors. TGEN looks like it has some good prospects, and if you lurk on the Yahoo thread, you already know that this recent pop means my shares are paid for...I've slid about ten grand worth off of the felt between the wife and me, and they'll stay in my pocket for the years ahead. By the way...when you and the rest of the biogurus here on SI are ready to start your fund, let me know. I've put a nice grubstake together, but the point is coming when I'll want to stop watching the markets. Anbody know if that McCamant fund has a symbol-- American Healthcare I think it is called...what is his performance like--anybody?